LÃ¦rke Smidt Gasbjerg

List of Publications by Year
in descending order

52 papers	1,573 citations	331259 21 h-index	315357 38 g-index
52 all docs	52 docs citations	52 times ranked	1336 citing authors

#	Article	IF	Citations
1	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. Pharmacological Research, 2022, 176, 106058.	3.1	13
2	Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake. Obesity Surgery, 2022, 32, 1385-1390.	1.1	0
3	GLP-1 and GIP receptor signaling in beta cells â€“ A review of receptor interactions and co-stimulation. Peptides, 2022, 151, 170749.	1.2	29
4	LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Reports Medicine, 2022, 3, 100582.	3.3	21
5	Worsening Postural Tachycardia Syndrome Is Associated With Increased Glucose-Dependent Insulinotropic Polypeptide Secretion. Hypertension, 2022, 79, HYPERTENSIONAHA12117852.	1.3	4
6	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism, 2022, 24, 1882-1887.	2.2	5
7	Nâ€terminal alterations turn the gut hormone GLPâ€2 into an antagonist with gradual loss of GLPâ€2 receptor selectivity towards more GLPâ€1 receptor interaction. British Journal of Pharmacology, 2022, 179, 4473-4485.	2.7	5
8	Doseâ€dependent efficacy of the glucoseâ€dependent insulinotropic polypeptide (<scp>GIP)</scp> receptor antagonist <scp>GIP</scp>(3â€30)<scp>NH₂</scp> on <scp>GIP</scp> actions in humans. Diabetes, Obesity and Metabolism, 2021, 23, 68-74.	2.2	14
9	The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology, 2021, 162, .	1.4	43
10	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. European Journal of Endocrinology, 2021, 184, 383-394.	1.9	15
11	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. European Journal of Endocrinology, 2021, 185, 23-32.	1.9	2
12	Effects of endogenous GIP in patients with type 2 diabetes. European Journal of Endocrinology, 2021, 185, 33-45.	1.9	21
13	Exendin(9â€39)<scp>NH₂</scp>: Recommendations for clinical use based on a systematic literature review. Diabetes, Obesity and Metabolism, 2021, 23, 2419-2436.	2.2	15
14	GIP and the gut-bone axis â€“ Physiological, pathophysiological and potential therapeutic implications. Peptides, 2020, 125, 170197.	1.2	25
15	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides, 2020, 125, 170183.	1.2	61
16	GIPâ€™s involvement in the pathophysiology of type 2 diabetes. Peptides, 2020, 125, 170178.	1.2	18
17	GIPâ€™s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3â€“30)NH2. Bone, 2020, 130, 115079.	1.4	20
18	Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides, 2020, 125, 170174.	1.2	27

#	Article	IF	Citations
19	Molecular interactions of full-length and truncated GIP peptides with the GIP receptor â€“ A comprehensive review. Peptides, 2020, 125, 170224.	1.2	27
20	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone, 2020, 140, 115553.	1.4	25
21	The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men. Alcohol, 2020, 87, 29-37.	0.8	4
22	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e725-e738.	1.8	37
23	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. Diabetes Care, 2020, 43, 588-596.	4.3	38
24	GIP(3-30)NH2 â€“ a tool for the study of GIP physiology. Current Opinion in Pharmacology, 2020, 55, 31-40.	1.7	8
25	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. Diabetes, 2020, 69, .	0.3	3
26	Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats. Frontiers in Endocrinology, 2019, 10, 492.	1.5	21
27	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia, 2019, 62, 665-675.	2.9	81
28	GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. Bone, 2019, 125, 178-185.	1.4	45
29	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2953-2960.	1.8	41
30	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes, 2019, 68, 906-917.	0.3	118
31	Gluco-metabolic effects of oral and intravenous alcohol administration in men. Endocrine Connections, 2019, 8, 1372-1382.	0.8	7
32	1976-P: Physiological Effects of GIP(1-30)NH2 in Healthy Subjects. Diabetes, 2019, 68, 1976-P.	0.3	1
33	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. Diabetes, 2019, 68, .	0.3	10
34	Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors. Biochemical Pharmacology, 2018, 150, 97-107.	2.0	65
35	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides, 2018, 100, 173-181.	1.2	56
36	The Combination of Fosfomycin, Metronidazole, and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor is Stable in vitro and Has Maintained Antibacterial Activity. Drug Research, 2018, 68, 349-354.	0.7	4

#	Article	IF	Citations
37	GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia, 2018, 61, 413-423.	2.9	66
38	The bile acidâ€sequestering resin sevelamer eliminates the acute <scp>GLP</scp>â€1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 362-369.	2.2	33
39	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. Diabetes, 2018, 67, 145-OR.	0.3	3
40	The Effect of Ethanol on Inflammation Markers and FGF-21 in Healthy Individuals. Diabetes, 2018, 67, .	0.3	0
41	GIP(3â€“30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release. Biochemical Pharmacology, 2017, 131, 78-88.	2.0	55
42	Effect of Intracoronary and Intravenous Melatonin on Myocardial Salvage Index in Patients with ST-Elevation Myocardial Infarction: a Randomized Placebo Controlled Trial. Journal of Cardiovascular Translational Research, 2017, 10, 470-479.	1.1	32
43	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. Cell Reports, 2017, 21, 1452-1460.	2.9	28
44	The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. Diabetes, 2017, 66, 2363-2371.	0.3	88
45	Signaling via G proteins mediates tumorigenic effects of GPR87. Cellular Signalling, 2017, 30, 9-18.	1.7	21
46	Speciesâ€specific action of (Pro3)GIP â€“ a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. British Journal of Pharmacology, 2016, 173, 27-38.	2.7	86
47	Nâ€terminally and Câ€terminally truncated forms of glucoseâ€dependent insulinotropic polypeptide are highâ€affinity competitive antagonists of the human GIP receptor. British Journal of Pharmacology, 2016, 173, 826-838.	2.7	72
48	Extracellular Disulfide Bridges Serve Different Purposes in Two Homologous Chemokine Receptors, CCR1 and CCR5. Molecular Pharmacology, 2013, 84, 335-345.	1.0	18
49	Biased and Constitutive Signaling in the CC-chemokine Receptor CCR5 by Manipulating the Interface between Transmembrane Helices 6 and 7. Journal of Biological Chemistry, 2013, 288, 12511-12521.	1.6	59
50	Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regulatory Peptides, 2012, 179, 91-100.	1.9	81
51	The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection. Frontiers in Endocrinology, 0, 13, .	1.5	1
52	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. Diabetes, 0, , .	0.3	1